Recently, two patented gene sequencers, the GS100 and GS200, developed by Cygnus Biosciences (Beijing) Co., Ltd., have officially been granted EU CE certification in compliance with the IVDR regulations, laying a solid foundation for the company to enter European and overseas markets.

The GS100 is a bench-top gene sequencer built on proprietary Fluorogenic and error-correcting code (ECC) technologies. It features long read lengths, high speed and high accuracy, with a data quality score of Q40 ≥ 85%. Compatible with mainstream library preparation kits, the gene sequencer supports a wide sample loading range and flexible throughput, making it suitable for most clinical and research applications.

The GS200 is also a gene sequencer that adopts Fluorogenic technology and incorporates the company's core Attoseal technology, reducing sequencing time by more than 20% with a minimum run time of only six hours. Its optical, biochemical and temperature control systems have been comprehensively upgraded, delivering a data quality score of Q40 ≥ 85%. The gene sequencer is compatible with mainstream libraries and supports multi-platform sharing and flexible operation. It can fulfill diverse testing requirements including metagenomic next-generation sequencing (mNGS), targeted next-generation sequencing (tNGS) and tumor panel testing.

Headquartered in the Beijing Economic-Technological Development Area, China, Cygnus Bio specializes in the independent research, development and industrialization of gene sequencing platforms, and owns a host of core technologies including Fluorogenic sequencing, ECC and Attoseal. The granting of CE certification for both the GS100 and GS200 gene sequencers marks a key milestone in the company's global expansion drive.